Remember Nanostim? It’s back – in a modified form, sold by a different company, and under another name.
The agency takes its time – particularly with diagnostics.
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.